- ￥2600
- AntibodySystem
- VHJ62501
- 2025年07月13日
- ELISA, Neutralization
- Human
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 抗体名：
InVivoMAb Anti-Human TREM1 & CD46 Bispecific Antibody (SAA2036)
- 抗体英文名：
InVivoMAb Anti-Human TREM1 & CD46 Bispecific Antibody (SAA2036)
- 浓度：
1 mg/ml
- 应用范围：
ELISA, Neutralization
- 适应物种：
Human
- 保质期：
1 year
- 级别：
科研级
- 库存：
999
- 供应商：
AntibodySystem
- 克隆性：
Monoclonal
- 亚型：
BiTE-bispecific antibody
- 规格：
100ug
| 种属反应性 | Human |
| 状态 | Liquid |
| 保存溶液 | 0.01M PBS, pH 7.4. |
| 浓度 | 1 mg/ml |
| 纯度 | >95% as determined by SDS-PAGE. |
| 克隆类型 | Monoclonal |
| 同种型 | BiTE-bispecific antibody |
| 应用 | ELISA, Neutralization |
| 靶标 | TREM1, Triggering receptor expressed on monocytes 1, Triggering receptor expressed on myeloid cells 1, TREM-1, CD354, Trophoblast leukocyte common antigen, CD46, TLX, MCP, Membrane cofactor protein, MIC10 |
| 纯化方式 | Purified by Nickel column. |
| 内毒素水平 | Please contact with the lab for this information. |
| Accession号 | Q9NP99 & P15529 |
| 稳定性和存储 | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term. |
| 克隆号 | SAA2036 |
| 备注 | For research use only. Not suitable for clinical or therapeutic use. |
Our products are designed for various research areas, supporting studies on 48 types of viruses, superbugs, parasites, cancer, Alzheimer's disease, Parkinson's disease, allergic responses, immune suppression, and immune activation.
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验[欢迎下载]：Antibody Engineering： Methods and Protocols
of Human Immunoglobulin Genes 7 Antibody Humanization by CDR Grafting 8 Selection of Human Antibodies from Phage Display Libraries 9 Production of Human Single-Chain Antibodies by Ribosome Display 10 Production of Human Antibodies from Transgenic Mice
【翻译】Development trends for monoclonal antibody cancer therapeutics
). However, since 2000, humanized and human mAbs have been entering clinical study at approximately the same rate (4.3 versus 4.5 mAbs per year, respectively). Figure 1 | Categories of monoclonal antibody cancer therapeutics entering clinical study during 1980–1989
Isolation of Human Fab Fragments Against Ovarian Carcinoma Using Guided Selection
on aspects such as mechanisms of action, preclinical screening, and clinical results, see specific references in Table 1 and an excellent recent review (1 ). Table 1 Target Antigens Potentially Suited for Antibody-Based Immunotherapy of Ovarian
技术资料暂无技术资料 索取技术资料
